DYNAVAX TECHNOLOGIES CORP Form 8-K November 14, 2006

Table of Contents

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES AND EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 12, 2006 DYNAVAX TECHNOLOGIES CORPORATION

(Exact name of registrant as specified in charter)

Delaware 000-50577 33-0728374

(State or other jurisdiction of incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

2929 Seventh Street, Suite 100 Berkeley, California 94710

(Address of principal executive offices and zip code)
Registrant s telephone number, including area code: (510) 848-5100

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

TABLE OF CONTENTS

Item 8.01. Other Events

Item 9.01. Financial Statements and Exhibits

SIGNATURES

INDEX TO EXHIBITS

EXHIBIT 99.1

Table of Contents

Item 8.01. Other Events.

In a press release dated November 12, 2006, the Company announced additional data from a Phase 2b study involving its TOLAMBA investigational therapy.

The press release dated November 12, 2006, titled Dynavax Reports New TOLAMBA Data at ACAAI Meeting, is attached hereto as Exhibit 99.1 and is herein incorporated by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. Description

99.1 Press Release, dated November 12, 2006, entitled Dynavax Reports New TOLAMBA Data at ACAAI

Meeting.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

Dynavax Technologies Corporation

Dated: November 13, 2006 By: /s/ Deborah A. Smeltzer

Deborah A. Smeltzer, Vice President, Operations and Chief Financial Officer

Table of Contents

INDEX TO EXHIBITS

Exhibit		
Number	Description	
99.1	Press Release, dated November 12, 2006, entitled	Dynavax Reports New TOLAMBA Data at ACAAI
	Meeting.	